Clinical ResearchCardiometabolic RiskReduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by Amgen, Inc. Dr. Raal has received consulting fees from Amgen, Inc., and Sanofi related to PCSK9 inhibitors; and his institution has received research funding related to PCSK9 inhibitor clinical trials from Amgen, Inc., and Sanofi. Dr. Giugliano has received honoraria for consulting and CME lectures from Amgen, Daiichi Sankyo, Bristol-Myers Squibb, Merck, Regeneron, and Sanofi; and participates in lipid research as a member of the TIMI Study Group, which has received research grant support for clinical trials from Amgen, Daiichi-Sankyo, and Merck. Dr. Sabatine has received grant support through Brigham and Women’s Hospital from Amgen, AstraZeneca, AstraZeneca/Bristol-Myers Squibb Alliance, Bristol-Myers Squibb/Sanofi Joint Venture, Daiichi Sankyo, Eisai, Genzyme, GlaxoSmithKline, Merck, Sanofi, Takeda, Abbott Laboratories, Accumetrics, Critical Diagnostics, Nanosphere, and Roche Diagnostics; and has consulted for Aegerion, Amgen, Diasorin, GlaxoSmithKline, Merck, Pfizer, Sanofi, AstraZeneca, and Vertex. Dr. Koren is an employee of Jacksonville Center for Clinical Research, which has received grants from Amgen Inc. Dr. Langslet is a consultant for and advisory board member of Janssen Pharmaceutical. Dr. Bays has consulted for and received speaker fees from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Catabasis, Daiichi Sankyo, Eisai Merck, VIVUS, and WBL Biotech Co.; and his research site has received grants from Alere, Amarin, Amgen, Ardea, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, California Raisin Board, Catabasis, Eisai, Elcelyx, Eli Lilly, Esperion, Essentialis, Forest, Gilead, Given, GlaxoSmithKline, High Point Pharmaceuticals LLC, Hoffman LaRoche, Home Access, Janssen, Merck, Micropharma Limited, Necktar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron, Stratum Nutrition, Takeda, TIMI, Transtech Pharma, Trygg, VIVUS, WBL Biotech Co., and Xoma. Dr. Blom has received consulting fees from Amgen Inc. and Sanofi related to PCSK9 inhibitors; has served on advisory boards of Amgen, Sanofi, Aegerion, and Merck, Sharpe, Dohme; has received speaker honoraria from Amgen, Aegerion, Merck, Sharpe, Dohme, Unilever, Pfizer, AstraZeneca, Ranbaxy, PharmaDynamics, and Sanofi; and his institution has received research funding related to PCSK9 inhibitor clinical trials from Amgen, Inc., and Sanofi. Dr. Eriksson has received lecture fees from Merck, Sharpe, Dohme and AstraZeneca and consulting fees from Amgen, Sanofi, and Novo Nordisk. Drs. Dent, Wasserman, Huang, Xue, Albizem, and Scott are employees of Amgen, Inc., and have received Amgen stock/stock options. Dr. Stein has received consulting fees from Amgen Inc., Adnexus Therapeutics/Bristol-Myers Squibb, Genentech/Roche, and Regeneron/Sanofi related to PCSK9 inhibitors.